Neurology
Vodobatinib (SCC-138)
Phase 2
c-ABL Inhibitor for Parkinson’s Disease
Vodobatinib (SCC-138)
Phase 2
c-ABL Inhibitor for Lewy Body Dementia
Vodobatinib (SCC-138)
Preclinical
c-ABL Inhibitor for Alzheimer’s Disease
Oncology
Vodobatinib
(SCO-088)
Phase 2
BCR-ABL Inhibitor for Refractory CML
SBO-154
Preclinical
Anti-MUC-1 ADC for Multiple Tumors
Immunology
Vibozilimod
(SCD-044)
Phase 2
Selective S1PR1 Agonist for Psoriasis
Vibozilimod
(SCD-044)
Phase 2
Selective S1PR1 Agonist for Atopic Dermatitis
SCD-153
Phase 2
Undisclosed for Alopecia Areata